Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2953678 | 0.83 | ADORA3 (0.38) | ADORA3CSNK2A1PARP1ALDH1A1L3MBTL1 | |
| SCHEMBL4239753 | 0.83 | PNP (0.34) | ADORA3CSNK2A1ALDH1A1ADORA1ADORA2A | |
| SCHEMBL10121590 | 0.80 | ADORA3 (0.32) | ADORA3ADORA1ADORA2A | |
| SCHEMBL3916442 | 0.79 | ADORA1 (0.30) | ADORA3ADORA1ADORA2A | |
| SCHEMBL12592352 | 0.79 | ADORA3 (0.35) | ADORA3CSNK2A1PARP1ALDH1A1L3MBTL1 | |
| SCHEMBL19633362 | 0.79 | CDK1 (0.37) | ADORA3CSNK2A1PARP1ALDH1A1L3MBTL1 | |
| SCHEMBL12726686 | 0.79 | CSNK2A2 (0.33) | ADORA3CSNK2A1ALDH1A1ADORA1ADORA2A | |
| SCHEMBL13522498 | 0.79 | ADORA1 (0.30) | ADORA3ADORA1ADORA2A | |
| SCHEMBL9797840 | 0.77 | ADORA3 (0.41) | ADORA3CSNK2A1ALDH1A1L3MBTL1ADORA1 | |
| SCHEMBL6423600 | 0.76 | NSD2 (0.40) | PARP1ALDH1A1L3MBTL1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705481-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-20250129308-A1 | SEMICONDUCTOR TREATMENT LIQUID, TREATMENT METHOD FOR OBJECT TO BE TREATED, AND MANUFACTURING METHOD OF ELECTRONIC DEVICE | FUJIFILM CORP (JP) | 2025-04-24 | — | — | US | claimed |
| WO-2024233308-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | claimed |
| WO-2024014224-A1 | SEMICONDUCTOR PROCESSING LIQUID, METHOD FOR PROCESSING OBJECT TO BE PROCESSED, AND METHOD FOR MANUFACTURING ELECTRONIC DEVICE | 富士フイルム株式会社 | 2024-01-18 | — | — | WO | claimed |
| CN-111741967-A | Nucleoside analogue, preparation method and application | 深圳市真迈生物科技有限公司 | 2020-10-02 | — | — | CN | claimed |
| US-9725474-B2 | Modified nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-08 | — | — | US | claimed |
| CN-106967068-A | N6The photochemistry demethyl method of methyl adenine | 中国科学院化学研究所 | 2017-07-21 | — | — | CN | claimed |
| WO-2016126987-A1 | COMPOSITIONS AND METHODS FOR SYNTHETIC GENE ASSEMBLY | Twist Bioscience Corporation (US) | 2016-08-11 | — | — | WO | claimed |
| US-9284343-B2 | 2′-O-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-03-15 | — | — | US | claimed |
| EP-2694524-A1 | 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2014-02-12 | — | — | EP | claimed |
| WO-2013071079-A1 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-05-16 | — | — | WO | claimed |
| EP-2547769-A1 | MINOR GROOVE BINDER (MGB)-OLIGONUCLEOTIDE MIRNA ANTAGONISTS | Elitech Holding B.V. (NL) | 2013-01-23 | — | — | EP | claimed |
| WO-2012138530-A1 | 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-10-11 | — | — | WO | claimed |
| WO-2011066312-A1 | MINOR GROOVE BINDER (MGB)-OLIGONUCLEOTIDE MIRNA ANTAGONISTS | ELITECH HOLDING B.V. (NL) | 2011-06-03 | — | — | WO | claimed |
| US-20050239727-A1 | for use in cosmetics, drugs | SILDEHA SWISS SA (CH) | 2005-10-27 | — | — | US | claimed |
| EP-1525224-A1 | HYALURONIC ACID DERIVATIVES | Jasper Ltd. Liability Co. (US) | 2005-04-27 | — | — | EP | claimed |
| WO-2004013182-A1 | HYALURONIC ACID DERIVATIVES | JASPER LTD LIABILITY CO. (US) | 2004-02-12 | — | — | WO | claimed |
| WO-2026106956-A1 | DISULFIDE-STABILIZED NOROVIRUS VIRUS-LIKE PARTICLE DESIGN | MERCK SHARP & DOHME LLC (US) | 2026-05-21 | — | — | WO | disclosed |
| US-4543388-A | Thermosettable polymers or prepolymers prepared from polymethylated pyrazines and aromatic polyaldehydes and cured products therefrom | THE DOW CHEMICAL COMPANY (US) | 1985-09-24 | — | — | US | disclosed |
| EP-0147689-A2 | A method of inducing antitumor immunocytes, and a process for producing antitumor immunocytes and antitumor immunocytes produced by the process | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1985-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239727-A1 | for use in cosmetics, drugs | HINT1, NUDT1, NNT | ADORA3 26/4885CSNK2A1 4747/4885PARP1 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.